PMID- 35892323
OWN - NLM
STAT- MEDLINE
DCOM- 20220728
LR  - 20220812
IS  - 2218-273X (Electronic)
IS  - 2218-273X (Linking)
VI  - 12
IP  - 8
DP  - 2022 Jul 22
TI  - The Role of ApoE Serum Levels and ApoE Gene Polymorphisms in Patients with 
      Laryngeal Squamous Cell Carcinoma.
LID - 10.3390/biom12081013 [doi]
LID - 1013
AB  - Recent studies have revealed that the inflammatory ApoE effect may play a 
      significant role in various cancer development. However, this effect has still 
      not been analyzed in patients with laryngeal squamous cell carcinoma (LSCC). In 
      the present study, we evaluated two single nucleotide polymorphisms (SNPs) of 
      ApoE (rs7412 and rs429358) and determined their associations with LSCC 
      development and the LSCC patients' five-year survival rate. Additionally, we 
      analyzed serum ApoE levels using an enzyme-linked immunosorbent assay. A total of 
      602 subjects (291 histologically verified LSCC patients and 311 healthy controls) 
      were involved in this study. The genotyping was carried out using the real-time 
      PCR. We revealed that ApoE epsilon3/epsilon3 was associated with a 1.7-fold higher 
      probability of developing LSCC (p = 0.001), with 1.7-fold increased odds of 
      developing LSCC without metastasis to the lymph nodes (p = 0.002) and with a 
      2.0-fold increased odds of developing well-differentiated LSCC (p = 0.008), as 
      well as 1.6-fold increased odds of developing poorly differentiated LSCC 
      development (p = 0.012). The ApoE epsilon2/epsilon4 and epsilon3/epsilon4 genotypes were associated with 
      a 2.9-fold and 1.5-fold decrease in the likelihood of developing LSCC (p = 0.042; 
      p = 0.037, respectively). ApoE epsilon3/epsilon4 was found associated with a 2.4-fold 
      decreased likelihood of developing well-differentiated LSCC (p = 0.013). 
      Conclusion: ApoE epsilon2/epsilon4 and epsilon3/epsilon4 were found to play a protective role in LSCC 
      development, while ApoE epsilon3/epsilon3 may have a risk position in LSCC development.
FAU - Liutkeviciene, Rasa
AU  - Liutkeviciene R
AD  - Neuroscience Institute, Lithuanian University of Health Sciences, LT-44307 
      Kaunas, Lithuania.
FAU - Auzelyte, Justina
AU  - Auzelyte J
AD  - Medical Academy, Lithuanian University of Health Sciences, LT-44307 Kaunas, 
      Lithuania.
FAU - Liutkevicius, Vykintas
AU  - Liutkevicius V
AD  - Department of Otorhinolaryngology, Lithuanian University of Health Sciences, 
      LT-44307 Kaunas, Lithuania.
FAU - Vilkeviciute, Alvita
AU  - Vilkeviciute A
AD  - Neuroscience Institute, Lithuanian University of Health Sciences, LT-44307 
      Kaunas, Lithuania.
FAU - Gedvilaite, Greta
AU  - Gedvilaite G
AD  - Neuroscience Institute, Lithuanian University of Health Sciences, LT-44307 
      Kaunas, Lithuania.
FAU - Vaiciulis, Paulius
AU  - Vaiciulis P
AD  - Department of Otorhinolaryngology, Lithuanian University of Health Sciences, 
      LT-44307 Kaunas, Lithuania.
FAU - Uloza, Virgilijus
AU  - Uloza V
AD  - Department of Otorhinolaryngology, Lithuanian University of Health Sciences, 
      LT-44307 Kaunas, Lithuania.
LA  - eng
PT  - Journal Article
DEP - 20220722
PL  - Switzerland
TA  - Biomolecules
JT  - Biomolecules
JID - 101596414
RN  - 0 (ApoE protein, human)
RN  - 0 (Apolipoprotein E2)
RN  - 0 (Apolipoprotein E3)
RN  - 0 (Apolipoproteins E)
SB  - IM
MH  - Apolipoprotein E2/genetics
MH  - Apolipoprotein E3/genetics
MH  - *Apolipoproteins E/genetics
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - *Laryngeal Neoplasms/genetics
MH  - *Polymorphism, Genetic
MH  - *Squamous Cell Carcinoma of Head and Neck/genetics
PMC - PMC9331506
OTO - NOTNLM
OT  - ApoE
OT  - laryngeal squamous cell carcinoma
OT  - rs7412 and rs429358
OT  - survival rate
COIS- The authors declare no conflict of interest.
EDAT- 2022/07/28 06:00
MHDA- 2022/07/29 06:00
PMCR- 2022/07/22
CRDT- 2022/07/27 04:52
PHST- 2022/06/14 00:00 [received]
PHST- 2022/07/13 00:00 [revised]
PHST- 2022/07/19 00:00 [accepted]
PHST- 2022/07/27 04:52 [entrez]
PHST- 2022/07/28 06:00 [pubmed]
PHST- 2022/07/29 06:00 [medline]
PHST- 2022/07/22 00:00 [pmc-release]
AID - biom12081013 [pii]
AID - biomolecules-12-01013 [pii]
AID - 10.3390/biom12081013 [doi]
PST - epublish
SO  - Biomolecules. 2022 Jul 22;12(8):1013. doi: 10.3390/biom12081013.